SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention due to recent advancements in its pipeline, including significant progress in tecarfarin manufacturing and a collaboration with Abbott for its pivotal Phase 3 trial targeting LVAD patients. While some investors are optimistic about its potential in the anticoagulation market, community sentiment also highlights concerns around the company's cash position, recent offerings, and the notable presence of bot activity amplifying its trend.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is generating significant buzz following reports of a substantial planned investment from the US government, which includes an equity stake aimed at strengthening the domestic rare earth supply chain. This is further amplified by news of an upcoming rare earth metals and alloys production facility in France, bolstered by government support. The community is actively discussing the potential for a massive stock surge and a short squeeze, reflecting strong sentiment around the company's strategic importance in securing critical mineral resources.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending following its mainnet migration to an EVM-compatible L2 on Arbitrum Orbit, positioning $JASMY as a custom gas token for AI and Web3 applications. This significant development has sparked intense debate, with many community members highlighting its foundational utility and regulatory backing in Japan as catalysts for a potential surge, while skeptics point to historical volatility and recent price action as typical 'pump and dump' behavior.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending amidst strong community excitement, primarily driven by rumors of a Coinbase listing and increasing institutional interest, with C2 Blockchain notably expanding its holdings. Enthusiasts are actively promoting it as the leading Bitcoin-native memecoin, emphasizing its fixed supply and decentralized nature as superior to other meme tokens and expressing high conviction for its long-term growth and potential to outperform.

Founded in 2018, Concordium is the Layer-1 blockchain built for a new era of digital trust.  Our name comes from the Latin concordia—meaning harmony and agreement—a reflection of our mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.  At the heart of Concordium is Smart Money: programmable digital assets with identity, policy controls, and compliance embedded at the protocol level. Smart Money enables frictionless digital interactions with security, automation, and regulatory certainty by design.  Concordium was established by Lars Seier Christensen, founder of Saxo Bank, inspired by the recognition that blockchain’s full potential can only be realized if it works with regulation, not against it. That insight led to a new model of trust—one where decentralization and accountability can coexist.  Backed by world-class cryptographic research and a global team with expertise across  blockchain, finance, and compliance, Concordium delivers protocol-native features like zero- knowledge verification, programmable compliance, and privacy-preserving controls—  empowering a smarter, more connected financial future.

Concordium

Concordium ($CCD) is trending as the community recognizes its unique position at the intersection of privacy, compliance, and real-world utility. Investors are highlighting its robust, regulation-ready infrastructure for PayFi and stablecoins, driven by strategic partnerships and built-in Zero-Knowledge Proofs. This focus on verifiable identity and accountability, rather than pure anonymity, is seen as crucial for institutional adoption and long-term relevance in a maturing crypto landscape.

The White Whale

WHITEWHALE is experiencing active community discussion around recent price volatility, with some attributing it to market manipulation and large-scale profit-taking. Despite this, a strong bullish sentiment persists, fueled by significant token burns, a substantial portion of supply locked long-term, and consistent growth in its holder base. The community largely views current dips as accumulation opportunities, reinforcing its belief in the token's long-term potential and legitimacy.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is actively discussed as a quantum computing leader following significant accumulation by institutional investors like BlackRock and its strategic advancement in government contracts. The company recently secured a $21.1 million Air Force project and joined the "Golden Dome" initiative, positioning itself as a full-stack quantum infrastructure provider, while its presence at CES 2026 highlights its commitment to commercial applications and ongoing community excitement.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as intense debate erupts over a recent fatal shooting involving federal agents in Minneapolis. Community members are sharply divided, with some condemning the incident as an unjustified act against a citizen and others defending the agents' response to alleged interference with federal operations. This contentious event fuels broader discussions about federal authority and political polarization, potentially impacting ongoing government funding debates.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is currently trending with active community discussion following its Breakthrough Therapy Designation for Pemvidutide in MASH and recent JPM Healthcare conference chatter regarding potential strategic partnerships or a buyout. Investors are debating whether this reflects the drug's "best-in-class" profile and significant market undervaluation, or if its recent price action is fueled by short covering and trading activity amidst ongoing data scrutiny.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is a trending topic amidst market chatter regarding proposed credit card interest rate caps and competition legislation. However, the community widely believes these measures will not directly impact Visa's core transaction-based revenue, as the company continues to showcase robust payments volume and strategic expansion into stablecoin settlements and AI-driven commerce. Investors are actively highlighting Visa's durable business model and its proactive innovations in the evolving digital payments ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.6% - Here's What Happened

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.6% - Time to Sell...

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Down - Time to Sell?

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Down - Here's Why...

Phathom Pharma Shows Sales Strength, Targets 2026 Profitability

Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.read more...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat...

Simplify Asset Management Inc. Reduces Position in Phathom Pharmaceuticals, Inc. $PHAT

Simplify Asset Management Inc. reduced its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 38.3% during the third quarter, according to its most recent filing with the...

Notable Monday Option Activity: PHAT, WHR, QBTS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Phathom Pharmaceuticals Inc (Symbol: PHAT), where a total of 5,492 contracts have traded...

Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT)

Raymond James Financial began coverage on Phathom Pharmaceuticals in a research report on Thursday. They issued a "strong-buy" rating and a $28.00 target price on the stock...

Frazier Life Sciences Management L.P. Purchases 2,357,210 Shares of Phathom Pharmaceuticals, Inc. $PHAT

Frazier Life Sciences Management L.P. lifted its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 23.3% in the 2nd quarter, according to the company in its most...

Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month High - What's Next?

Phathom Pharmaceuticals (NASDAQ:PHAT) Hits New 52-Week High - Here's What Happened...

683 Capital Management LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. $PHAT

683 Capital Management LLC grew its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 45.7% during the 2nd quarter, according to the company in its most recent disclosure with...

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

Current Price	$13.50
Prev Close	$14.19
Open	$14.27
Dividend Yield	0.00%
50-Day Moving Average	$15.31
Beta	1.25
Avg. Volume	921,331.05
PE Ratio	-3.54

52-Week High	$18.31
52-Week Low	$2.21
Market Capitalization	$1.06B
EPS (Annual)	-$5.29
Price to Book	-2.27
Revenue Per Employee	$129,395.79
Enterprise Value/EBITDA	N/A

PHAT
Phathom Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PHAT News

PHATPhathom Pharmaceuticals Inc